GenomAI
GenomAI is a US precision medicine AI company providing a multimodal oncology AI platform that integrates genomics, pathology, imaging, and clinical records to deliver evidence-based treatment recommendations for oncologists, cancer centers, individuals and families, and biotech and pharma clients.
- Company typePrivate
- Founded2023
- HeadquartersDanville, United States
- Headcount1–10
- GTM typeB2B and B2C
- OfferingSoftware
What GenomAI does
GenomAI is a US-based precision medicine AI company founded in 2023 that operates an oncology-specialized artificial intelligence platform unifying genomics, pathology, imaging, and clinical records into evidence-based treatment recommendations. The company positions its product as the first precision oncology AI platform built exclusively for cancer care, deploying a multimodal AI architecture composed of multiple specialized reasoning agents (biomarker interpretation, treatment optimization, imaging analysis, and trial matching) that collaborate like a multidisciplinary care team and produce consensus-backed recommendations reported at 99% concordance with expert tumor boards and 100% NCCN guideline accuracy. The platform embeds directly into major EHR systems with bidirectional data flow and a 30-day integration guarantee, and a privacy-first architecture that runs entirely on-premise on a single 8GB GPU without transmitting PHI externally, enabling deployment in rural clinics, field hospitals, and other resource-limited environments.
The company serves three primary customer segments: healthcare providers including NCI-designated cancer centers, academic medical centers, and over 500 community oncology practices; individuals and families seeking whole-genome clinical analysis and AI health guidance; and business and government clients including biotech and pharmaceutical firms. Its consumer-facing offering covers 17,000+ diseases through FDA and CAP-approved Illumina whole-genome sequencing of 3.2 billion DNA base pairs, while business modules include variant analysis, drug performance prediction, trial matching, and outcomes tracking.
GenomAI monetizes through a mix of per-patient and per-case fees, multi-year enterprise site licenses for cancer centers, value-based pricing tied to measurable outcomes, and self-service ordering for individuals, supplemented by a refund guarantee on case fees. Distribution combines enterprise field sales targeting IT and oncology leadership at large institutions with inside sales for smaller practices and consumers, plus a web interface for international and research users. The company holds HIPAA-aligned (architecture-level), CAP, CLIA, and EU-US Data Privacy Framework certifications, is a US SAM Federal and California-certified small business, and operates with a 1-10 person headcount based in Danville, USA.
GenomAI firmographics
Firmographics- Name
- GenomAI
- Legal name
- GenomAI
- Website
- https://genom-ai.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- GenomAI is a US precision medicine AI company providing a multimodal oncology AI platform that integrates genomics, pathology, imaging, and clinical records to deliver evidence-based treatment recommendations for oncologists, cancer centers, individuals and families, and biotech and pharma clients.
- Ownership category
- akta.pro rank
GenomAI industry classification
Industry- Product category
- Precision Oncology AI Platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), Computer Systems Design and Related Services (54151)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Prepackaged Software (7372)
- akta.pro primary industry
- Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics) (HLAAANAF)
- akta.pro secondary industries
- Bioinformatics & Multi-omics Analysis Software (HLAGAJAD), Molecular Tumor Boards & Clinical Interpretation Services (HLAAANAD), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
Keywords
Where GenomAI is headquartered
LocationHeadquarters
- HQ city
- Danville
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
GenomAI business model
Business model- GTM type
- B2B and B2C
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Per-Patient/P Per-Case Pricing: Per-patient pricing model for comprehensive precision oncology support. Most community practices prefer per-case or per-patient models. Case fees are refundable if unhappy with analysis.
- Enterprise Site Licenses: Enterprise site licenses for cancer centers and academic medical centers. Most academic centers use enterprise licensing for broad institutional deployment.
- Value-Based Pricing: Value-based pricing tied to measurable outcomes. Flexible pricing model for healthcare organizations focused on results-driven partnerships.
- Refund Guarantee Revenue Model: If GenomAI's analysis does not meet satisfaction, case fees are refunded in full. Demonstrates confidence in precision oncology AI quality.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Per case | Per-patient pricing for comprehensive precision oncology support |
| Subscription | Multi-year contract | Enterprise site licenses for cancer centers |
| Outcome Based/ Performance | Annual | Value-based pricing tied to measurable outcomes |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels4 records
GenomAI product offering
Product offeringCore offering
GenomAI builds a precision oncology AI platform that integrates genomics, pathology, imaging, lab values, and EHR clinical notes through multiple specialized generative AI reasoning agents to deliver NCCN-aligned, evidence-based treatment recommendations, clinical trial matching, and tumor-board-level decision support embedded in provider EHR workflows. For individuals and families, the company offers a Clinical AI Assistant for 24/7 health guidance and Clinical Graded Genome Analysis using FDA/CAP-approved Illumina whole genome sequencing covering 17,000+ diseases. For biotech, pharma, and government clients, GenomAI provides variant analysis, drug performance prediction, trial matching, and outcomes tracking delivered through a privacy-first architecture that runs on-premise with zero PHI transmitted externally.
Product overview
GenomAI is a precision oncology AI platform that unifies genomic data, clinical records, imaging, and lab results into actionable health insights. The core GenomAI platform serves healthcare providers with tumor-board-level decision support and individuals/families with genome analysis and AI health assistance. Provider-side modules include EHR integration, tumor board preparation tools, and case analysis. Individual/family offerings include the Clinical AI Assistant, Clinical Graded Genome Analysis (Illumina WGS, 3.2 billion base pairs, 17,000+ diseases), Clinical Records Integration, and Treatments/Clinical Trials Access. Business segments include Variant Analysis, Drug Performance Prediction, Trial Matching, and Outcomes Tracking for biotech and pharma. All offerings emphasize on-premise/privacy-first deployment with HIPAA-aligned architecture and no cloud data routing.
Differentiator
Problem solved
Functional benefit
Products and services
- GenomAI Precision Oncology Platform World's first precision oncology AI platform built exclusively for cancer care that integrates genomic data, clinical history, pathology reports, imaging studies, and oncology documentation into real-time, evidence-based treatment recommendations embedded directly into provider EHR workflows. Designed for oncologists, NCI-designated cancer centers, community oncology practices, and government healthcare systems, with bidirectional data flow and 30-day EHR integration guarantee.
- Clinical AI Assistant AI-powered conversational assistant for individuals and families that provides 24/7 interactive health guidance, interprets medical records in plain English, and validates responses against a proprietary clinical database with supporting medical research citations. Designed for patients seeking personalized health insights, family risk assessment, and second opinions on medical recommendations.
- Clinical Graded Genome Analysis Comprehensive whole genome sequencing service using FDA and CAP approved Illumina WGS technology to analyze 3.2 billion DNA base pairs and 69,000 genes, covering 17,000+ diseases verified by the Institute National of Medicine. Delivers health risk assessment for individuals and family members seeking hereditary and chronic disease insights.
- Treatments and Clinical Trials Access Direct access service for individuals and families to FDA approved treatment options and clinical trials matched to their genetic profile and medical history, with information formatted for discussion with healthcare providers. Trials are updated daily from ClinicalTrials.gov and institutional databases.
- Variant Analysis for Biotech and Pharma Identifies exact pathogenic variants and related variants from GenomAI's proprietary database that can impact drug efficacy and patient response, supporting drug development workflows for biotechnology and pharmaceutical organizations.
- Drug Performance Prediction Predicts drug performance based on comprehensive genetic variant analysis, enabling personalized treatment optimization and supporting drug development and clinical research decisions for biotech and pharma clients.
- Clinical Trial Matching for Biotech and Pharma Matches patients to relevant clinical trials based on genetic profile for biotech and pharma sponsors, ensuring optimal participant selection and trial success rates. Trials are updated daily from ClinicalTrials.gov and institutional databases.
- Real-World Outcomes Tracking Tracks treatment effectiveness and patient outcomes by monitoring EHR data to continuously improve drug development and clinical trial design for biotech and pharma clients.
Quantifiable outcome
- Reduces diagnostic time by 40%
- +6 more outcomes
Companies that use GenomAI
Customer profileNamed customers3 records
Segments5 records
Ideal customer profiles5 records
GenomAI technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability10 records
Feature8 records
GenomAI partnerships and signals
Strategic signalScale indicators11 records
Recent moves6 records
Expansion highlights6 records
GenomAI competitors and assessment
Company assessmentEmerging players
- TwoScan: TwoScan is an early-stage AI health companion platform that pairs genomics analysis with conversational AI for individuals and clinicians, comparable in scope to GenomAI's consumer-facing Clinical AI Assistant and genome analysis workflow.
- Paige.AI: Paige.AI provides AI-driven digital pathology solutions for cancer diagnosis, including FDA-authorized applications — directly comparable to GenomAI's pathology and imaging interpretation capabilities.
- Arterys: Arterys delivers cloud and on-premise medical imaging AI for oncology and radiology workflows, comparable to GenomAI's CT/PET/MRI imaging analysis and offline deployment capabilities.
- Owkin: Owkin uses AI and federated learning on multimodal patient data (imaging, genomics, clinical) to support oncology research and drug development, paralleling GenomAI's multimodal reasoning-agent architecture.
- MolecularMatch: MolecularMatch provides AI-powered clinical trial matching and molecular decision support for oncology patients, overlapping with GenomAI's Clinical Trial Matching Engine and trial-eligibility agent.
Direct peers
- PathAI: PathAI develops AI-based pathology analysis used in cancer diagnosis and biomarker discovery, comparable to GenomAI's pathology report analysis and AI-powered cancer care agents.
- Tempus AI: Tempus AI is a leading precision medicine company that combines genomic sequencing, clinical data, and AI to support oncology decision-making, including treatment selection and clinical trial matching — directly analogous to GenomAI's precision oncology platform.
- Caris Life Sciences: Caris Life Sciences offers molecular profiling (MI Profile) and AI-driven multi-omics analytics to support precision oncology treatment selection, closely paralleling GenomAI's multi-omics platform and tumor-board decision support.
- Foundation Medicine: Foundation Medicine provides comprehensive genomic profiling and molecular diagnostics used by oncologists to guide targeted therapy selection, a core use case of GenomAI's biomarker interpretation and treatment recommendation agents.
- Flatiron Health: Flatiron Health is an oncology-specific EHR and real-world data company that powers evidence-based cancer care and clinical research, comparable to GenomAI's oncology EHR-integrated AI decision support offering.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks7 records
Key highlights7 records
Customer concentration
GenomAI social profiles
Digital presenceGenomAI compliance and trust
Trust signalCompliance5 records
GenomAI financial estimates
Financial estimateRevenue estimate
Valuation estimate
GenomAI leadership team
Management profileNumber of profiles
GenomAI funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GenomAI M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GenomAI
What does GenomAI do?
GenomAI builds a precision oncology AI platform that integrates genomics, pathology, imaging, lab values, and EHR clinical notes through multiple specialized generative AI reasoning agents to deliver NCCN-aligned, evidence-based treatment recommendations, clinical trial matching, and tumor-board-level decision support embedded in provider EHR workflows. For individuals and families, the company offers a Clinical AI Assistant for 24/7 health guidance and Clinical Graded Genome Analysis using FDA/CAP-approved Illumina whole genome sequencing covering 17,000+ diseases. For biotech, pharma, and government clients, GenomAI provides variant analysis, drug performance prediction, trial matching, and outcomes tracking delivered through a privacy-first architecture that runs on-premise with zero PHI transmitted externally.
Is GenomAI a public or private company?
GenomAI is a private company. It is classified as unknown and is currently operating.
When was GenomAI founded?
GenomAI was founded in 2023. It employs 1 to 10 people.
Where is GenomAI based?
GenomAI is headquartered in Danville, United States, in the North America region.
How does GenomAI make money?
Four revenue lines are on record. Per-Patient/P Per-Case Pricing is the primary driver. The others are enterprise Site Licenses, value-Based Pricing and refund Guarantee Revenue Model.
Who are GenomAI's main competitors?
Emerging players on record are TwoScan, Paige.AI, Arterys, Owkin and MolecularMatch. Direct peers are PathAI, Tempus AI, Caris Life Sciences, Foundation Medicine and Flatiron Health.
Does GenomAI have an API?
No public API is recorded for GenomAI.
What industry is GenomAI in?
GenomAI's product category is Precision Oncology AI Platform. Its primary akta.pro industry code is HLAAANAF, Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics), with a secondary code of HLAGAJAD, Bioinformatics & Multi-omics Analysis Software. Its NAICS code is 541714 and its SIC code is 2835.